Drugs Xagena
Incivo is a medicine that contains the active substance Telaprevir ; it is used to treat chronic hepatitis C ( a disease of the liver due to infection with the hepatitis C virus [ HCV ] ) in combinati ...
Xofigo is a radiopharmaceutical ( a medicine containing a radioactive substance ) that contains the active substance Radium-223 dichloride. It is used to treat adult men with cancer of the prostate. X ...
Pradaxa is a medicine that contains the active substance Dabigatran etexilate; it is used to prevent the formation of blood clots in the veins in adults who have had an operation to replace a hip or k ...
The FDA ( Food and Drug Administration ) has approved Diclegis ( Doxylamine and Pyridoxine ) to treat pregnant women experiencing nausea and vomiting.Diclegis is a delayed-release tablet intended for ...
The Food and Drug Administration ( FDA ) has approved Procysbi ( Cysteamine bitartrate ) for the management of nephropathic cystinosis in children and adults.Procysbi was granted orphan product design ...
The FDA ( Food and Drug Administration ) has approved Kcentra ( Prothrombin Complex Concentrate, Human ) for the urgent reversal of vitamin K antagonist ( VKA ) anticoagulation in adults with acute ma ...
Bayer HealthCare has announced that the FDA ( Food and Drug Administration ) has approved Xofigo ( Radium 223 dichloride ) for the treatment of patients with castration-resistant prostate cancer ( CRP ...
Eliquis is a medicine that contains the active substance Apixaban; it is used to prevent venous thromboembolism in adults following a hip or knee replacement operation.Eliquis is also used to prevent ...
Stivarga is an anticancer medicine that contains the active substance Regorafenib. It is used to treat metastatic colorectal cancer in adults who have already been treated with, or who cannot be given ...
Xarelto is a medicine that contains the active substance Rivaroxaban; it is used for the following in adults : to prevent venous thromboembolism ( VTE ) in patients who are undergoing surgery to repla ...
Significant liver injury associated with the use of Tolvaptan ( Samsca ) has been reported. In a large double-blind, 3-year, placebo-controlled trial ( TEMPO 3:4 ) in about 1400 patients with autosoma ...
The European Committee for Medicinal Products for Human Use ( CHMP ) has recommended approval of oral anticoagulant Xarelto ( Rivaroxaban ) 2.5 mg twice-daily in combination with standard antiplatelet ...
The Food and Drug Administration ( FDA ) warned the public that Azithromycin ( Zithromax or Zmax ) can cause abnormal changes in the electrical activity of the heart that may lead to a potentially fat ...
The FDA ( Food and Drug Administration ) has approved Kadcyla ( Trastuzumab Emtansine ), a new therapy for patients with HER2-positive, late-stage ( metastatic ) breast cancer.HER2 is a protein involv ...
The FDA ( Food and Drug Administration ) has approved a new use of Avastin ( Bevacizumab ) in combination with fluoropyrimidine-based Irinotecan or Oxaliplatin chemotherapy for people with metastatic ...
The Committee for Medicinal Products for Human Use ( CHMP ) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Relvar Ellipta, 184 mcg/22 mcg ...
The investigational compound, Lu AE58054 is a selective 5HT6 receptor antagonist with a different proposed mechanism of action than currently available Alzheimer's medications. Notably, a focus on the ...
Inflectra, a biosimilar medicine to the reference medicinal product, Remicade ( Infliximab ), has been approved for the treatment of inflammatory conditions including rheumatoid arthritis, ankylosing ...
Ruxolitinib ( Jakafi ) is an oral, selective inhibitor of Janus kinases 1 and 2 ( JAK1 and JAK2 ). Ruxolitinib, brand name Jakafi, is indicated for treatment of patients with intermediate or high-risk ...
Denosumab ( Prolia ) is a human monoclonal antibody ( IgG2 ) that targets and binds with high affinity and specificity to RANKL, preventing activation of its receptor, RANK, on the surface of osteocla ...
Melbourne researchers have discovered that anti-cancer compounds currently in clinical trials for some types of leukaemia could offer hope for treating the most common type of breast cancer. The re ...
A second large, prospective study by researchers at Fred Hutchinson Cancer Research Center has confirmed the link between high blood concentrations of Omega-3 fatty acids and an increased risk of pros ...
Pharmacodynamic and safety data from a Phase 2 proof-of-concept study of its investigational factor Xa inhibitor antidote Andexanet alfa ( PRT4445 ) in healthy volunteers who were administered the fac ...
The U.S. Food and Drug Administration ( FDA ) has granted accelerated approval of Iclusig ( Ponatinib ) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leu ...
The FDA ( U.S. Food and Drug Administration ) has approved Picato ( Ingenol mebutate ) gel ( 0.015%, 0.05% ) for the topical treatment of actinic keratosis. Actinic keratosis is a precancerous condi ...
The European Commission ( EC ) has granted marketing authorisation for Flutiform ( Fluticasone propionate / Formoterol fumarate ), a new combination therapy for the maintenance treatment of asthma, in ...
Currently, there are no Factor X inhibitors approved for indication to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome. There are three P2Y12 inhibitors ...
The FDA ( Food and Drug Administration ) has approved Stribild ( Elvitegravir 150 mg / Cobicistat 150 mg / Emtricitabine 200 mg / Tenofovir disoproxil fumarate 300 mg ), a complete once-daily single t ...
The European Commission has granted marketing authorisation to Zinforo ( Ceftaroline fosamil ), a new intravenous cephalosporin antibiotic, for the treatment of adult patients with complicated skin an ...
Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ), also known as VEGF Trap-Eye, has been approved by the European Commission ( EU ) for the treatment of patients with ne ...
Forxiga ( Dapagliflozin ) is the first SGLT2 ( sodium/glucose cotransporter 2 ) class drug. Forxiga has obtained marketing approval by the European Commission ( EC ) for the treatment of type 2 diabet ...
European Commission has granted Votrient ( Pazopanib ) marketing authorisation for the treatment of patients with advanced soft tissue sarcoma ( aSTS ) who have received prior chemotherapy or have pro ...
European Commission has granted marketing authorization to Jentadueto, which combines the DPP-4 inhibitor, Linagliptin and Metformin in a single tablet. Linagliptin and Metformin hydrochloride is a ne ...
The FDA ( Food and Drug Administration ) has approved Myrbetriq ( Mirabegron ) extended-release tablets for the treatment of overactive bladder ( OAB ) with symptoms of urge urinary incontinence, urge ...
Patients with acute rhinosinusitis are frequently encountered in primary care. Although corticosteroids are being increasingly used for symptom control, evidence supporting their use is inconclusive. ...
The FDA ( Food and Drug Administration ) has approved Kyprolis ( Carfilzomib ) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade ...
The American College of Physicians ( ACP ) has developed a clinical practice guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of type ...
The FDA ( Food and Drug Administration ) has approved Xtandi ( Enzalutamide ) to treat men with late-stage ( metastatic ) castration-resistant prostate cancer that has spread or recurred, even with me ...
European Commission ( EC ) has approved oral anticoagulant Xarelto ( Rivaroxaban ) for the treatment of pulmonary embolism ( PE ) and the prevention of recurrent deep vein thrombosis ( DVT ) and pulmo ...
The FDA ( Food and Drug Administration ) has approved the anti-clotting drug Eliquis ( Apixaban ), an oral tablet used to reduce the risk of stroke and dangerous blood clots ( systemic embolism ) in p ...
The FDA ( Food and Drug Administration ) has approved Pertuzumab injection ( Perjeta ) for use in combination with Trastuzumab and Docetaxel for the treatment of patients with HER2-positive metastatic ...
The FDA ( Food and Drug Administration ) has approved Synribo ( Omacetaxine mepesuccinate ) to treat adults with chronic myelogenous leukemia ( CML ).An estimated 5,430 people will be diagnosed with c ...
On 18 October 2012, the CHMP ( Committee for Medicinal Products for Human Use ) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Betmiga ...
Votubia is a medicine that contains the active substance Everolimus. It is available as tablets ( 2.5, 5, 10 mg ). Votubia is used to treat the following benign tumours caused by the genetic disease t ...
Key safety concerns with Denosumab ( Xgeva ) included in the Warnings and Precautions section of the existing product labeling involve the risks of osteonecrosis of the jaw ( ONJ ) and hypocalcemia. O ...
Bayer HealthCare has announced that the Food and Drug Administration ( FDA ) approved Stivarga ( Regorafenib ) tablets for the treatment of patients with metastatic colorectal cancer ( mCRC ) who have ...
The FDA ( Food and Drug Administration ) has approved Omontys ( Peginesatide ) to treat anemia in adult dialysis patients who have chronic kidney disease ( CKD ). Omontys is a new erythropoiesis-st ...
The European Commission ( EC ) has approved Eliquis ( Apixaban ) for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( NVAF ) with one or more risk f ...
The Food and Drug Administration ( FDA ) has approved Zyclara cream for the treatment of external genital and perianal warts ( EGW ) in patients 12 years of age and older. Zyclara cream’s clinical s ...
The European Commission has granted approval for the use of ALIMTA ( Pemetrexed for injection ) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer ...
